Product Description
Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Institute of Allergy and Infectious Diseases (NIAID)
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Malaria, Falciparum
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01169077 |
N01AI80005C | P1 |
Completed |
Malaria, Falciparum |
2012-07-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|